I hate shopping prescription drugs for schizophrenia Baird analyst Jeffrey Elliot upgraded his rating on thebiotechnology company's stock to "outperform" from "neutral"saying Chief Executive Chuck Kummeth's strategy, including hisplans to invest in China and other emerging markets, is a goodopportunity for growth.